Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Cash & Equivalents (2016 - 2025)

Lipocine's Cash & Equivalents history spans 14 years, with the latest figure at $3.9 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 80.32% year-over-year to $3.9 million; the TTM value through Sep 2025 reached $3.9 million, down 80.32%, while the annual FY2023 figure was $22.0 million, 31.54% down from the prior year.
  • Cash & Equivalents reached $3.9 million in Q3 2025 per LPCN's latest filing, down from $6.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $33.7 million in Q3 2022 to a low of $3.0 million in Q4 2021.
  • Average Cash & Equivalents over 5 years is $15.7 million, with a median of $17.7 million recorded in 2021.
  • Peak YoY movement for Cash & Equivalents: crashed 84.38% in 2021, then skyrocketed 969.19% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $3.0 million in 2021, then surged by 969.19% to $32.1 million in 2022, then crashed by 31.54% to $22.0 million in 2023, then fell by 9.73% to $19.8 million in 2024, then crashed by 80.32% to $3.9 million in 2025.
  • Per Business Quant, the three most recent readings for LPCN's Cash & Equivalents are $3.9 million (Q3 2025), $6.0 million (Q2 2025), and $19.7 million (Q1 2025).